CRISPR cures, longevity science, lab-grown meat, and the Nobel-winning research rewriting medicine.
Biology has become an engineering discipline. Gene editing can now cure diseases once thought untreatable, billions are flowing into reversing aging, and meat grown in bioreactors is on store shelves.
This hub collects all of our biotech and health coverage: CRISPR cures going mainstream, the longevity bet and what actually works, the optogenetics Nobel, and the strange new world of cultivated meat.
The science is moving faster than the policy, the pricing, or the public conversation. We are tracking all of it. Bookmark this page; it updates every time we publish a new biotech story.
Aging is being reframed from inevitable decline to treatable condition. The science is early, the money is enormous, and the first real tests are underway.
One-time genetic cures for sickle cell, blindness, and more are here. Now comes the harder question: who can afford them?
Molecules come in left- and right-handed versions, and your body can tell the difference. Two chemists figured out how to make chemistry pick the right one, and it changed drug-making forever.
Flash blue light on a single brain cell and watch it fire. Three scientists turned pond algae into the most precise tool neuroscience has ever had.
After years of promises, cultivated meat is actually for sale. We tried it. The results were surprising.
Billions are flowing into aging research. We separated the real science from the expensive wishful thinking.
CRISPR is a gene-editing tool that can correct disease-causing mutations. One-time cures for sickle cell disease, inherited blindness, and beta thalassemia are now approved, but each costs $2 million to $4 million per patient. The science works; the manufacturing and delivery economics for personalized treatments have not caught up.
Ex vivo editing removes a patient's cells, edits them in a lab, and reinfuses them. It is grueling and expensive. In vivo editing delivers the editor directly inside the body with an injection, which is simpler logistically. The field is moving toward in vivo delivery for exactly that reason.
Yes. Cultivated meat grown from animal cells in bioreactors has reached store shelves in some markets, produced without slaughter. Taste and price remain the open questions: early products are premium-priced, and scaling production down to commodity prices is the industry's central challenge.
Billions are flowing into reversing aging, but the evidence base is thin for most interventions. What has real support: exercise, sleep, and managing metabolic health. Most longevity drugs and supplements remain unproven in humans, which is why separating the science from the hype matters.